Amgen Hones In On Denosumab Sales And Payer Strategies Ahead Of Launch
This article was originally published in The Pink Sheet Daily
Executive SummaryBiotech estimates 500 to 1,000 sales reps will be needed to commercialize the osteoporosis injectable in the U.S.
You may also be interested in...
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.